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Abstract The treatment of osteoporotic patients with
teriparatide is associated with a signiﬁcant increase in bone
formation and gain of bone mass. The purpose of this post
hoc analysis was to determine if the cross-sectional area
(CSA) of the spinal canal and the vertebral body is affected
by teriparatide treatment. Narrowing of the spinal canal
might represent a safety problem, while widening of the
vertebral CSA might improve mechanical stability. High-
resolution computed tomography (HRCT) scans of vertebra
T12 were obtained at baseline and after 6, 12, and
24 months of teriparatide treatment (20 lg/day) from 44
postmenopausal women with established osteoporosis
participating in the prospective, randomized EUROFORS
study. The CSA of the spinal canal did not decrease but
increased marginally by 0.9% (2.6 mm
2) over 24 months
(P\0.001), with a range from -0.5% (-2m m
2) to 3.1%
(?8m m
2). Even when analyzing the spinal CSA on a
slice-by-slice basis, no clinically relevant narrowing of the
spinal canal was observed. For vertebral bodies, the CSA
increased by 0.7% (5.7 mm
2) over 24 months (P\0.001),
with a range from -0.4% (–3 mm
2) to 1.6% (?14 mm
2).
Our data do not provide evidence for safety concerns
regarding spinal canal narrowing. On the other hand, the
increases observed for vertebral CSA apparently also only
minimally contribute to the mechanical strengthening of
the vertebral body under teriparatide treatment.
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Introduction
Several studies show that the treatment of osteoporotic
patients with teriparatide results in substantial gain of bone
mineral density (BMD) in the vertebral bodies [1, 2]. BMD
can be measured by quantitative computed tomography
(QCT) or dual X-ray absorptiometry (DXA). The increases
in BMD, bone fraction, and microstructural variables [3]
point to an increase in trabecular and cortical bone thick-
ness. It is not clear if and how much the overall size and
shape of a vertebra changes under teriparatide treatment.
Rehman et al. [4] reported an increase in the vertebral body
cross-sectional area (CSAvb) by analyzing QCT data of
postmenopausal women with glucocorticoid-induced oste-
oporosis treated with hPTH(1–34). However, estimation of
only the overall size in one slice of the vertebra (mid-
vertebral area) and the lower resolution of QCT images
may not be sufﬁcient for more detailed conclusions con-
cerning different regions of the vertebra, like the entire
vertebral body or the spinal canal.
Apposition of bone on the cortical surface caused by
teriparatide-stimulated remodeling might lead to enhanced
growth into the spinal canal in general or at local areas and
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in CSAvb, one might argue that there might also be the risk
of bone apposition at the border of the spinal canal. In
patients with a narrow spinal canal this might increase the
risk for neural complication. To approach a repeatedly
encountered clinical question, i.e., if treatment with teri-
paratide might bear a risk of spinal canal stenosis, we
studied changes in CSA for both vertebral bodies and the
spinal canals (CSAsc), using the more sensitive imaging
method high-resolution computed tomography (HRCT).
This analysis was conducted in postmenopausal women
with established osteoporosis who participated in the pro-
spective, randomized European Study of Forsteo (EU-
ROFORS) [5, 6].
Materials and Methods
CSAsc and CSAvb of thoracic vertebra T12 were measured
with HRCT at baseline and after different time intervals
during therapy. An average CSAsc was used to determine
the general change per patient. Local variations were
analyzed by comparison of individual CT slices.
EUROFORS was a pan-European, multicenter, con-
trolled, prospective, randomized open-label clinical trial of
postmenopausal women with severe osteoporosis of
2 years’ duration. A subgroup of participants was subjected
to HRCT scanning of vertebra T12 at baseline and after 6,
12, and 24 months. The patients differed in their osteopo-
rosis medication history prior to study start; the majority
had received extensive pretreatment with antiresorptive
medication, which had to be discontinued at study start.
Details have been described elsewhere [3]. For quality-
assurance (QA) purposes the Mindways QA calibration
phantom (Mindways, Austin, TX) was measured on each
scanner. Analysis of its central bone-equivalent region
permitted cross-calibration of BMD and area data across
centers and tracking of stability over time (e.g., impact of
equipment change). For the present analysis, only patients
treated with teriparatide (20 lg/day) over the complete
duration of 2 years were included. An additional pre-
requisite was a valid baseline scan and at least two valid
follow-up scans, including a valid scan at 24 months. For
both spinal canal and vertebral body analyses, 44 patients
were available. The HRCT examinations of T12 were
obtained at 120 kV and 360 mAs using CT scanners from
Siemens (Erlangen, Germany) and GE (Milwaukee, WI)
(located at seven different centers). The reconstructed
slice thickness ranged from 300 to 500 lm, and the size of
the in-plane resolution was 156 9 156 lm
2 or 188 9
188 lm
2. The entire volume was covered by approximately
30–50 slices for the spinal canals and 40–70 slices for the
vertebral bodies (Fig. 1a).
As a ﬁrst step of the analysis, all baseline images of the
vertebrae were aligned in the same orientation. The spinal
canal was aligned parallel to the z-axis and the symmetry
axis of the vertebra, parallel to the x-axis. Next, all follow-
up images were registered to their corresponding baseline
images. This allowed exact slice-by-slice comparisons. For
this purpose an automatic 3D rigid registration method
from the ITK Insight Segmentation and Registration
Toolkit [7] was used.
For segmentation of the spinal canal and the vertebral
body an active contour or snake model [8, 9] was used. In
order to deﬁne an initial contour, several preprocessing
steps were necessary. The overall shape of the vertebra was
found via binarization (by thresholding) of the 3D image
and a 3D labeling algorithm. The labeling algorithm was
used to ﬁnd the largest connected component, which was
the vertebra. From each 2D slice of the labeled binary
image initial contours for the snake algorithm were
obtained. The snake algorithm operated on the gradient
image derived from the original image. The snake contour
is attracted by the local gradient, in this case the gray value
gradient between the spinal canal and bone or the gradient
between the outer area and the vertebral body. After sev-
eral steps of calculation, the snake moved to the maximum
gradient. Some restrictions had to be deﬁned to achieve a
Fig. 1 Overview of a vertebra. a Coronal view of a vertebral body
with ranges of evaluable slices for CSA analysis. b Segmented CSA
of the spinal canal and the vertebral body. The posterior border of the
vertebral body is deﬁned by an artiﬁcial boundary line
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123higher accuracy. As shown in Fig. 1b, for vertebral body
segmentation a posterior straight border had to be deﬁned
since the true posterior border is ill-deﬁned in the region of
the spinous processes. For the spinal canal segmentation
boundaries were also necessary on those image slices
where no closed spinal canal area existed: a posterior
border typically in the caudal part of the vertebra (Fig. 2a)
and an anterior border where the snake algorithm failed
because of holes and porosity in the inner cortical wall,
often in the cranial part of the vertebral body (Fig. 2b).
Typically, 50 and 30% of the slices of a patient required
setting an anterior border or a posterior border, respec-
tively. All parameters, e.g., borderlines, snake elasticity,
and threshold, were kept exactly the same for all slices of a
given patient. All calculations on the images were per-
formed by the same operator (R. S.).
To obtain a measure of the accuracy of the technique,
the variability of the measurement process was estimated
by ﬁtting a cubic spline through the CSA function plotted
against the superposed slices for several scans (Fig. 3). The
node points were chosen in such a way that the spline
function was sufﬁciently smooth.
As a measure of reproducibility of the area measure-
ments, we calculated the long-term precision error for the
participants of the study. This parameter was derived from
the standard error of the estimate of a linear ﬁt of the lon-
gitudinal data of a given patient. It thus represents a worst-
case estimate because any nonlinear change will also con-
tribute to the precision error. The long-term precision error
ofthegroupswasthenderivedasarootmeansquareaverage
of the results of the study participants’ reference [10].
All statistical analyses were performed with JMP 7.0 and
8.0(SASInstitute,Cary,NC).Exploratoryone-sample,two-
sided t-tests were conducted to assess the treatment effect.
Results
Of the 44 women (mean age ± SD 68.0 ± 6.7 years)
included for this analysis, 37 were pretreated with some
form of antiresorptive medication prior to study start. One
patient had to be excluded from the spinal canal analysis
because of substantial imaging artifacts in the baseline
image. Another patient could not be used for area mea-
surements of the vertebral body due to an invalid recon-
structed ﬁeld of view (FOV). Two follow-up scans at 6 and
12 months had to be discarded for CSAvb measurements.
The segmentation algorithm failed completely in a few
single slices for CSAsc and CSAvb measurements, and
thus, these slices could not be included in the ﬁnal analysis.
These failures were clearly recognizable and sorted out
manually and automatically (e.g., large deviations of[30%
to adjacent slices or corresponding temporal slices). All
automatically discarded slices were checked by inspection.
For 18 patients, the posterior border had to be set to restrict
the variability of the snake algorithm (Fig. 2b).
For the accuracy error of the area measurements, the
estimated variability was 3 mm
2 (1%) for CSAsc and
Fig. 2 Artiﬁcial boundaries for the spinal canal. a Lower boundary, b
upper boundary. For a given patient, these lines were positioned
consistently across all time points
Fig. 3 Representative example of the CSA of a vertebral body along
adjacent slices. The ﬁtted spline function was used to estimate the
root mean square error, in this case 2.5 mm
2
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2 (0.5%) for CSAvb. Assuming a round area, this
would correspond to errors in the radius of 0.05 and
0.04 mm, respectively, which is about one-third of the
pixel length given here. The long-term precision error
amounted to 4.4 mm
2 (0.53%) for the area measurement of
the vertebral body and 1.2 mm
2 (0.41%) for the area
measurement of the spinal canal.
For analysis on a patient-by-patient basis, an average
area (mm
2) was determined for the baseline visit and the
follow-up visits for each patient. For each of the follow-up
visits the absolute and percentage changes compared to
baseline were determined and are listed in Table 1.A s
early as 12 months after initiation of teriparatide treatment,
small but steadily growing increases in CSA were observed
for the vertebral bodies and spinal canals (Table 1). There
were two patients with baseline CSAs that were consider-
ably larger than those of the other patients (3–3.5 SD above
the baseline mean of all other patients), but they showed
similar patterns of change over time compared to the other
patients (1.2% increase and 0.5% decrease in CSAsc,
respectively).
In order to investigate the changes in CSAsc in more
detail, we also tried to match individual CT slices and
determined the corresponding changes in CSA since
baseline. Figure 4 presents histograms of percent changes
between baseline and follow-up visits analyzed on a slice-
by-slice basis. In total, 1,666 slices for CSAsc and 2,280
slices for CSAvb were evaluated. For a closer inspection of
a potential local narrowing of the spinal canal, images
corresponding to extreme results of the slice-by-slice
analysis were examined. These images, as represented by
the extreme values in the left tails of the histogram dis-
tributions in Fig. 4, showed an inaccurate segmentation
typical for a noise signal rather than a visible apposition of
bone. Further, these extreme values were not found in a
few speciﬁc vertebrae only but were widely spread across
many different vertebrae. For example, the four most
extreme values with reductions in spinal area of a single
slice between -7 and -5% occurred in vertebrae of three
different patients with corresponding mean CSA changes
of 0.5, 0.5, and 0.2%. Outliers moved back to the normal
range at the next time point.
To test whether the increases in CSA would be due to
systematic shifts in the magniﬁcation of the CT images
over time, we compared the CSA of the rigid bone phan-
tom positioned under the patient in reconstructions with a
lower resolution. While there was variability across scan-
ners, this could not explain the increases observed for
CSAvb and CSAsc. Increases in these two CSAs correlated
only weakly, with Pearson R
2 = 0.28. About 40% of all
patients were examined in one center where the scanner
was replaced by a new one of the same brand after the 12-
month visit. The increase in CSAvb and CSAsc from this
center’s 24-month visit was larger than the increase
obtained from the remaining centers. Evaluation of the
central region of the calibration phantom showed that the
new scanner seemed to overestimate the central area by
approximately 0.3% compared to the old one. In an anal-
ysis restricted to data from all other remaining centers,
Table 1 Absolute baseline values, mean differences, and relative increases of the CSA for the 43 patients available for analysis
CSA Value at baseline (mm
2) Mean difference (mm
2) after Mean increase (%) after
6 months 12 months 24 months 6 months 12 months 24 months
sc (patient) 291.4 ± 46.0 0.1 ± 1.2* 1.0 ± 1.5 2.6 ± 2.6 0.02 ± 0.40* 0.35 ± 0.49 0.91 ± 0.88
vb (patient) 822.6 ± 154.3 1.5 ± 2.5 2.9 ± 3.0 5.7 ± 4.2 0.18 ± 0.30 0.35 ± 0.35 0.69 ± 0.48
All values are given as mean ± SD for the spinal canal (sc) and the vertebral body (vb) areas. All area changes were highly signiﬁcant
(P\0.0001) except for CSAsc after 6 months
* Not signiﬁcant compared to baseline
Fig. 4 Percent changes in CSA of the spinal canal, evaluated on a
slice-by-slice basis (1,666 slices from 43 patients) and displayed as
histograms
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123CSA results of all visits still did not decrease but increased
steadily from their baseline result, with signiﬁcant changes
(P\0.05) observed after month 12. At 24 months the
increases measured here were 0.50% for CSAsc and 0.48%
for CSAvb compared to 1.51% for CSAsc and 0.93% for
CSAvb for the center with the scanner change, leaving the
overall effect in the range of ?0.5 to ?1.5%.
We also tested whether the increase in CSAvb was
associated with the baseline status of degenerative changes
at the vertebral bodies, speciﬁcally the presence of osteo-
phytes on the outer border of the vertebral body. As shown
in Fig. 5, patients who already had degenerative changes at
baseline (n = 13) showed a signiﬁcantly larger increase in
CSAvb than patients without such degenerative changes at
baseline (n = 30) based on t-tests. After 24 months, the
increase in CSAvb amounted to 0.98% for the group with
degenerative changes at baseline, which was larger
(P\0.01) than the 0.56% increase observed for the group
without degenerative changes at baseline.
Discussion and Conclusion
The results presented here demonstrate that 2 years of
teriparatide treatment were associated with very small
changes of CSA of both the T12 vertebral body as well as
the spinal canal. For none of the patients could a tendency
be detected that the treatment might cause a narrowing
which could result in stenosis of the spinal canal. On the
contrary, a small but clinically irrelevant enlargement of
the spinal canal was measured after 12 and 24 months,
similar to the increase in CSAvb. The average increase was
\1% for both areas (\3 and 6 mm
2 for CSAsc and CSAvb,
respectively). These results are consistent with observa-
tions in the manufacturer’s spontaneous adverse event
database [11], where after approximately 1 million patient
years of exposure to teriparatide, the onset or worsening of
symptoms of spinal stenosis has been reported rarely, with
most cases also reporting preexisting spine disease. These
reports, together with the ﬁndings of the present study,
seem to suggest that narrowing or stenosis of the spinal
canal is a very rare event that is not affected by teriparatide
treatment. One should bear in mind that the measured
changes are in the range of the estimated accuracy error of
the technique of 3 mm
2 or 1%. A uniform apposition of
bone of only one pixel would account for 3–4% of change.
Thus, the extreme values of single-slice changes in CSAsc
of -7 to –5% for only a handful of slices are all within the
likelihood of a measurement error. This assumption is
further supported by the observation that these extreme
values were spread across several patients and that they
moved back to the normal range at the next time point.
An averaging effect of the contour-ﬁnding procedure
and the evaluation over several slices decreased the vari-
ability of results. This enabled us to detect very small
changes in the patient-by-patient analysis, where CSAsc
changes ranged between -0.5 and 3.1% (-2 and ?8m m
2)
and CSAvb changes ranged between -0.4 and 1.6% (-3
and ?14 mm
2).
Still, some questions remain. The fact that a small
increase in CSAsc was observed is surprising and docu-
ments that teriparatide treatment does not induce bone
apposition on all cortical surfaces. Possibly, vertical
mechanical stresses might lead to a stretching effect on the
vertebrae due to compression of the material. Alternatively,
due to its concave shape, the outer border of the spinal canal
might also be mechanically considered like an endocortical
surface with corresponding resorption in the remodeling
process. However, these explanations at this time are rather
speculative and demand more detailed investigations. We
also considered potential technical reasons for these chan-
ges. For example, increases in BMD may affect edge
detection. The changes between BMD, vertebral area, and
spinal canal area were positively correlated within a given
patient. Therefore, one might speculate that the observed
increase in vertebral area may in part have been caused by
edge-detection effects caused by the increase in BMD
during treatment. However, unlike the vertebral body,
which is bone tissue surrounded by soft tissue, the spinal
canal is a space that is surrounded by bone and, thus, such
edge-detection effects would have led to a decrease in the
area of the spinal canal. Thus, the consequence would be
opposite to what was observed for the spinal canal. BMD
changes can thus be disregarded as a potential cause for
artiﬁcial increases in area of the spinal canal.
Fig. 5 Difference in increases in CSA of the vertebral bodies
between group of patients without (n = 30) and with (n = 13)
degenerative changes on the outer border of the vertebral bodies at the
baseline visit. There was no signiﬁcant difference between the groups
at months 6 and 12. Signiﬁcant changes were observed at 24 months
(P\0.01)
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123The separate analysis of vertebrae with and without
degenerative changes on the outer border suggests that the
degenerative processes inﬂuence the results. Therefore, the
true teriparatide-associated increase of the CSAvb would
be even smaller than the sub-1% range reported here.
Degenerative changes are quite common in this age group,
and it would be expected that those patients with higher
levels of degenerative changes at baseline would also be
more prone to show progression over time. The effects
were very small, amounting to only 8 mm
2 or 1% of the
CSAvb at baseline. Since teriparatide is given for 2 years
or less, this should have little relevance clinically. In fact,
since there was no untreated control group, we cannot
exclude the possibility that there is no teriparatide-induced
periosteal apposition at all. On the other hand, this analysis
documents that QCT is a sensitive tool to study the tem-
poral development of small degenerative changes at the
vertebral body.
To our knowledge, this is the ﬁrst study on CSAsc
measurement to monitor treatment effects. For the CSAvb
under treatment with hPTH(1–34) earlier results were
presented by Rehman et al. [4]. They observed an increase
in vertebral size of 5%, a ﬁnding which cannot be con-
ﬁrmed by our results.
Tatarek [12] used the anterior–posterior and the trans-
verse distance of the spinal canal in individual skeletons for
determining the variations associated with sex and ancestry
and to deﬁne cervical narrowing. The assignment of these
distances on HRCT images instead of CSA would involve
a much higher variability and dependence on the operator
(if performed manually).
One advantage of the automatic image-processing
methods applied here is the 3D rigid registration of the
images. It prevents any impact of the vertebrae’s individual
orientations on the measurement variables and allows exact
analysis on a slice-by-slice basis. Although the success of
the registration could not be quantiﬁed, visual inspection of
the different images showed perfect matching in most
cases. Failed registration could be easily identiﬁed and
corrected.
Nevertheless, there are shortcomings in this study which
provide room for improvements. In the area of image pro-
cessing the introduction of artiﬁcial borderlines for the
segmentation was required. They were used for spinal canal
segmentation because for two images the resulting differ-
ence in CSA measured with a ﬁxed but known line is more
reliable than the outcome measured with an ill-deﬁned
curve (inﬂuenced by noise, lack of distinct local gradient).
For the vertebral body, the delineation of the pedicles and
the difﬁculties in segmentation of the inner porous wall
necessitated the use of a straight boundary. The inﬂuence of
this part of the boundary was negligible since for a given
patient it was applied consistently across all time points.
Another problem regards the CT scanners. In one center
the CT scanner had to be exchanged during the course of
the study. Such equipment change might have had an
impact on the geometrical changes observed during the
study. However, separate analyses carried out for this
center and all remaining centers documented the limited
effect of this equipment change. Statistical analysis
restricted to the remaining centers still yielded the same
qualitative results, leaving the overall effect in the range
of ?0.5 to ?1.5%. One might also point out that there was
no control group in this study. However, for the following
reasons we believe that this is not a critical deﬁciency for
the main outcome, the lack of narrowing of the spinal
canal area. First of all, there is no physical reason for
changes in the geometry and voxel sizes on CT scanners.
In addition, this was controlled by monitoring a solid
calibration phantom positioned underneath the patients.
No relevant change in magniﬁcation could be observed for
the CSAs of the calibration rods of this phantom. More-
over, our results would not be likely to be different if they
were compared to a control group for the following rea-
son. If a control group would show no change in area or a
decrease in area over time, the teriparatide results would
hold up or even look more positive. If the control group
showed a larger positive change in canal area, we would
still be left with a spinal canal area in teriparatide-treated
patients that did not decrease. Such a scenario could be
explained only by natural age-related increases in spinal
canal, which would in part be counteracted by teriparatide
treatment. Even in this case the spinal canal area would
not be compromised during a treatment that matched the
clinically approved therapy scheme employed in the EU-
ROFORS study. The lack of a control may affect some of
the secondary ﬁndings of the study. Indeed, the small
increases in area might be an artifact of the study group.
However, as pointed out above, the magnitudes of the
changes are so small that they do not carry much clinical
relevance anyway.
A more fundamental limitation of our study was the
restriction to an analysis of just one vertebra, T12. While
we cannot exclude that different CSA changes could be
observed for other vertebrae, we do not see a physiological
reason for such differences. Moreover, our analysis was
limited to the spinal canal, excluding the space between
adjacent vertebrae.
In summary, we measured the CSA of the spinal canal
and vertebral body T12 of 44 postmenopausal women over
24 months of teriparatide treatment. HRCT data were used
for 3D assessment of changes in CSA with submillimeter
accuracy. Treatment with teriparatide was associated with
a very small, clinically irrelevant increase of CSAsc and
CSAvb, the latter potentially partially caused by degener-
ative changes, in the range of 0.5–1.5%. There was no
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123evidence for an increased risk of spinal canal narrowing
associated with 2 years of daily teriparatide treatment.
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